Photocure ASA
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHCUF research report →
About the company
Photocure ASA, a specialty pharmaceutical company established in Oslo, Norway in 1993, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing, distribution, and commercialization. The company's reach extends across the Nordic countries, major European markets like Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, as well as the United States. Key offerings include Hexvix/Cysview, which is used for the identification and ongoing care of bladder cancer.
- CEO
- Daniel Schneider
- IPO
- 2013
- Employees
- 99
- HQ
- Oslo, NO
Price Chart
- Market Cap
- $159.91M
- P/E
- 18.55
- P/S
- 2.33
- P/B
- 2.71
- EV/EBITDA
- 7.27
- Div Yield
- 0.00%
- Gross Margin
- 92.48%
- Op Margin
- 26.90%
- Net Margin
- 12.55%
- ROE
- 16.63%
- ROIC
- 21.62%
- Revenue
- $532.28M · 1.31%
- Net Income
- $-1,518,137 · 68.44%
- EPS
- $-0.06 · 68.61%
- Op Income
- $109.98M
- FCF YoY
- -84.72%
- 52W High
- $7.39
- 52W Low
- $5.15
- 50D MA
- $6.83
- 200D MA
- $6.49
- Beta
- 0.35
- Avg Volume
- 64
Get TickerSpark's AI analysis on PHCUF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PHCUF coverage
Recent articles, reports, and earnings notes.
No research on PHCUF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHCUF report →Similar companies
Peers in the same neighborhood.